An evaluation of anti-diabetic and anti-lipidemic properties of Momordica charantia (bitter melon) fruit extract in experimentally induced diabetes

Life Science Journal

Volumn 9, Issue 2, 2012, Pages 363-374

  Mohammady, Ibraheem ^a   Elattar, Samah ^a   Mohammed, Sanaa ^b   Ewais, Madeha ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b BENI SUEF UNIVERSITY   (Egypt)

Author keywords

Diabetes; Glucose absorption; Momordica charantia; Rat diaphragm glucose uptake; Rosiglitazone maleate

Indexed keywords

EID: 84874833176     PISSN: 10978135     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes, estimates for the year 2000 and projections for 2030, Diabetes Care. 2004; 27(5): 1047-53.
2. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000; 5; 283(13):1695-702.
3. Maghrani M., Lemhadri A, Zeggwagh N A, El-Amraoui M, Jouad H and Eddouks M. Effect of an aqueous extract of Triticum repens on lipid metabolism in normal and recent-onset diabetic rats. J. Ethnopharmacol. 2004; 90(2-3): 331-7.
4. Mallare JT, Karabell AH, Velasquez-Mieyer P, Stender SRS Christensen ML. Current and future treatment of metabolic syndrome and Type 2 diabetes in children and adolescents, Diabetes Spectr. 2005; 18(4): 221-5.
5. Murphy JM. Preoperative considerations with herbal medicines. American Organization of Registered Nurses Journal. 2000; 69:173-83.
6. Karunanayake EH, Tennekoon KH. Search of novel hypoglycaemic agents from medicinal plants, in: A.K. Sharma (Ed.), Diabetes Mellitus and its Complications-An update, Macmillan India 2003: 192-6.
7. Jayasuriya AP, Sakono M, Yukizaki C, Kawano M, Yamamoto K, Fukuda N.-Effects of Momordica charantia powder on serum glucose levels and various lipid parameters in rats fed with cholesterol-free and cholesterol-enriched diets. J Ethnopharmacol. 2000; 72 (1-2):331-6.
8. Welihinda J, Karunanayake EH, Sheriff MH, Jayasinghe KS. Effect of Momordica charantia on the glucose tolerance in type 2 diabetes. J Ethnopharmacol. 2006; 17:277-82.
9. Pitipanapong, J, Chitprasert S. Goto M, Jiratchariyakul W, Sasaki M, Shotipruk A. New approach for extraction of charantin from Momordica charantia with pressurized liquid extraction. Separat Purification Technol. 2007; 52: 416-22.
10. Paul A, Raychaudhuri SS, Medicinal uses and molecular identification of two Momordica charantia varieties-a review. E J Biol. 2010; 6(2): 43-51.
11. Cheng, H. A cell-based screening identifies compounds from the stem of Momordica charantia that overcome insulin resistance and activate AMP-activated protein kinase. J Agric Food Chem. 2008; 56(16): 6835-43.
12. Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia. 2000; 43(3):278-84.
13. Sheweita AA, Newairy HA, Mansour MI. Effect of some hypoglycemic herbs on the activity of phase I and II drug-metabolizing enzymes in alloxan induced diabetic rats Toxicology. 2002; 174: 131-9.
14. Chen Q, Li ETS. Reduced adiposity in bitter melon (Momordica charantia) fed rats is associated with lower tissue triglyceride and higher plasma catecholamines British Journal of Nutrition. 2005; 93: 747-54.
15. Leatherdale B A, Panesar R K, Singh G, Atkins T W, Bailey C J, Bignell A H. Improvement in glucose tolerance due to Momordica charantia (karela). Br Med J (Clin Res Ed). 1981 June 6; 282 (6279): 1823-4.
16. th Ed. Tietz NW (Ed.) W. B. Sounders company, Philadalphia, pp. 283-335.
17. Nauck M, Graziani MS, Jarausch J, Bruton D, Cobbaert C, Cole TG, Colella F, Lefevre F, Gillery P, Haas B, Law T, König M, Macke M, März W, Meier C, Riesen W, van Vliet M, Wieland H, Rifai N. A new liquid homogeneous assay for HDL cholesterol determination evaluated in seven laboratories in Europe and the United States. Clin Chem Lab Med. 1999; 37(11-12):1067-76.
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry. 1972; 18: (6): 499-502.
19. Seifter S, Dayton S, Novic B, Muntwyler E. The estimation of glycogen with the anthrone reagent. Arch Biochem. 1950; 25:191-200.
20. Abraham EC, Rao KR. Glycosylated hemoglobins in a diabetic patient with sickle cell anemia. Clin Physiol Biochem. 1987; 5(6):343-9.
21. Zarzuelo A, Risco S, Gamez MJ, Jimenez J, Camara M, Martinez MA. Hypoglycemic action of Salvia lavandulifolia vahl. ssp. Oxyodon: a contribution to studies on the mechanism of action. Life Sci., 1990; 47:909-15.
22. Bancroft JD, Stevens A. Theory and practice of histological techniques. 2nd edition. Chruchill Liveingstone 1982. Pp: 374-5.
23. Howell SL, Taylor K W. Potassium ions and the secretion of insulin by islets of Langerhans incubated in vitro. Biochem. J. 1968; 108: 17-24.
24. Lashin O, Andrea R. Mitochondria respiration and susceptibility to ischemia-reperfusion injury in diabetic hearts. Arch Biochem Biophys, 2003; 420: 298-304.
25. Umrani D N, Bodiwala DN and Goyal RK. Effect of sarpogrelate on altered STZ-diabetes induced cardiovascular responses to 5-hydroxytryptamine in rats. Mol Cell Biochem. 2003; 249(1-2): 53-7.
26. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res. 2001; 50 (6):537-46. Review.
27. Sambandam N, Abrahani MA, Craig S, Al-Atar O, Jeon E, Rodrigues B. Metabolism of VLDL is increased in streptozotocin-induced diabetic rat hearts. Am J Physiol Heart Circ Physiol. 2000; 278 (6):H1874-82.
28. Jouad H, Eddouks M, Lacaille-Dubois MA, Lyoussi B. Hypoglycaemic effect of Spergularia purpurea in normal and streptozotocin-induced diabetic rats. J Ethnopharmacol. 2000 Jul; 71(1-2):169-77.
29. Beck-Nielsen H. Insulin resistance: organ manifestations and cellular mechanisms. Ugeskr Laeger. 2002; 15; 164(16):2130-5. Review.
30. Raju J, Gupta D, Rao AR, Yadava PK and Baquer NZ. Trigonella foenum graecum (fenugreek) seed powder improves glucose homeostasis in alloxan diabetic rat tissues by reversing the altered glycolytic, gluconeogenic and lipogenic enzymes. Mol Cell Biochem. 2001; 224(1-2): 45-51.
31. Glombitza KW, Mahran GH, Mirhom YW, Michel KG and Motawi T K Hypoglycemic and antihyperglycemic effects of Zizyphus spina-christi in rats. Planta Med. 1999; 60: 244-7.
32. Nakura H, Tanaka M, Tateishi T, Watanabe M, Kumai T, Kobayashi S. The effects of streptozotocin-induced hypoinsulinemia on serum lipid levels in spontaneously hyperlipidemic rats. Horm Metab Res. 1997; 29(9):454-7.
33. Feilleux-Duche S, Garlatti M, Burcelin M, Aggerbeck M, Bouguet J, Girard J, Harnoune J and Barouki R. Acinar zonation of the hormonal regulation of cytosolic aspatrtate aminotransferase in liver. Am. J. Physiol. 2004; 266: C911-8.
34. Rawi SM, Abdel-Moneim A and Ahmed O M. Studies on the effect of garlic oil and glibenclamide on alloxan-diabetic rats. 2-Biochemical effects. Egypt J Zool. 1998; 30: 211-28.
35. Fernandes PC, Lagishetty CV, Panda VS, Naik SR. An experimental evaluation of the antidiabetic and antilipidemic properties of a standardized Momordica charantia fruit extract. BMC Complement Altern Med. 2007; 7: 29.
36. Yuan XQ, Gu XH, Tang J, Wasswa J. Hypoglycemic effects of semipurified peptides from Momordica charantia. J Food Biochem. 2008; 32(1):107-21.
37. Dans AM, Villarruz MV, Jimeno CA, Javelosa MA, Chua J, Bautista R, Velez GG. The effect of Momordica charantia capsule preparation on glycemic control in type 2 diabetes mellitus needs further studies. Med Monatsschr Pharm. 2007; 30(4):131-7.
38. Sundaram EN, Kumar S. Bitter melon holds hope for treating diabetes. Homeopathic Society. 2002; 22: 4.
39. Garau C, Cummings E, David A. Phoenix, Jaipaul Singh. Beneficial effect and mechanism of action of Momordica charantia in the treatment of diabetes mellitus: a mini review. Am J Health Syst Pharm., 2003; 60:356-9.
40. Yibchok-anun S, Adisakwattana S, Yao CY, Sangvanich P, Roengsumran S, Hsu WH. Slow Acting Protein Extract from Fruit Pulp of Momordica charantia with Insulin Secretagogue and Insulinomimetic Activities. Biol Pharmaceut Bull. 2006; 29 (6):1126.
41. Hui H, Tang G, Liang V. Hypoglycemic herbs and their mechanisms of action. Chinese Medicine. 2009; 4:11.
42. Toshihiro M, Chisa I, Naoki I, Motoshi K, Rae PS, Ikukatsu S. Hypoglycemic activity of the fruit of the Momordica charantia in type 2 diabetic mice. J Nutr Sci Vitaminol. 2001; 47(5):340-4.
43. Subratty AH, Gurib-Fakim A, Mahmoodally F. Bitter melon: an exotic vegetable with medicinal values. JNFS. 2005; 35 (3):143-7.
44. Singh N, Gupta M. Regeneration of beta cells of pancrease of alloxan diabetic rats by acetone extract of M. charantia fruits. Indian J. Exp. Biol. 2007; 45:1055-62.
45. Karunanayake EH, Jeevathayaparan S, Tennekoon KH. Effect of Momordica charantia fruit juice on streptozotocin-induced diabetes in rats. J Ethnopharmacol., 1990; 30(2):199-204.
46. Xiang L, Huang X, Chen L, Rao P, Ke L. The reparative effects of Momordica charantia Linn. extract on HIT-T15 pancreatic beta cells. Asia Pac J Clin Nutr. 2007; 16 Suppl 1:249-52.
47. Chaturvedi P, George S, Milinganyo M, Tripathi YB. Effect of Momordica charantia on lipid profile and oral glucose tolerance in diabetic rats. Phytother Res. 2004 Nov; 18(11):954-6.
48. Ahmed I, Adeghate E, Cummings E, Sharma AK, Singh J. Beneficial effects and mechanism of action of Momordica charantia juice in the treatment of streptozotocin-induced diabetes mellitus in rat. Mol Cell Biochem. 2004; 261(1-2):63-70.
49. Shih CC, Lin CH, Lin WL, Wu JB. Momordica charantia extract on insulin resistance and the skeletal muscle GLUT4 protein in fructose-fed rats. J Ethnopharmaco. 2009; 123(1): 82-90.
50. Chuang CY, Hsu C, Chao CY, Wein YS, Kuo YH, Huang CJ. Fractionation and identification of 9c, 11t, 13t-conjugated linolenic acid as an activator of PPARalpha in bitter gourd (Momordica charantia L.). J Biomed Sci. 2006; 13(6):763-72.
51. Tan MJ, Ye JM, Turner N, Hohnen-Behrens C, Ke CQ, Tang CP, Chen T, Weiss HC, Gesing ER, Rowland A, James DE, Ye Y. Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. Chem Biol. 2008; 15(3):263-73.
52. Mahomoodally MF, Gurib-Fakim A, Subratty AH Effect of exogenous ATP on Momordica charantia Linn. (Cucurbitaceae) induced inhibition of D-glucose, L-tyrosine and fluid transport across rat everted intestinal sacs in vitro. J Ethnopharmacol. 2007; 110(2):257-63.
53. Shetty AK, Kumar GS, Sambaiah K, Salimath PV Effect of bitter gourd (Momordica charantia) on glycaemic status in streptozotocin induced diabetic rats. Plant Foods Hum Nutr. 2005; 60(3):109-12.
54. Matsuda H, Shimoda H, Ninomiya K, Yoshikawa M. Inhibitory mechanism of costunolide, a sesquiterpene lactone isolated from Laurus nobilis, on blood-ethanol elevation in rats: involvement of inhibition of gastric emptying and increase in gastric juice secretion. Alcohol. 2002; 37(2):121-7
55. Rathi SS, Grover JK, Vats V. The effect of Momordica charantia and Mucuna pruriens in experimental diabetes and their effect on key metabolic enzymes involved in carbohydrate metabolism. Phytother Res. 2002; 16(3):236-43.
56. Reynet C, Kahn CR and Loeken MR. Expression of the gene encoding glycogen phosphorylase is elevated in diabetic rat skeletal muscle and is regulated by insulin and cyclic AMP. Diabetologia. 1996; 39: 183-9.
57. Newairy AS, Mansour HA, Yousef MI, Sheweita SA. Alterations of lipid profile in plasma and liver of diabetic rats: effect of hypoglycemic herbs. J Environ Sci Health B. 2002 Sep; 37(5):475-84
58. Wasan KM, Ng SP, Wong W and Rodrigus BB. Streptozotocin and alloxan-induced diabetes modifies total plasma and lipoprotein lipid concentration and composition without altering cholesterol ester transfer activity. Pharmacol Toxicol. 1998; 83(4): 169-75.
59. Capeau J. Insulin resistance and steatosis in humans. Diabetes Metab. 2008; 34(6 Pt 2):649-57. Review
60. Balkis Budin S, Othman F, Louis SR, Abu Bakar M, Radzi M, Osman K, Das S, Mohamed J. Effect of alpha lipoic acid on oxidative stress and vascular wall of diabetic rats. Rom J Morphol Embryol. 2009; 50(1):23-30.
61. Van Linthout S, Spillmann F, Schultheiss HP, Tschöpe C. High-density lipoprotein at the interface of type 2 diabetes mellitus and cardiovascular disorders. Curr Pharm Des. 2010; 16(13):1504-16.
62. Ouviña SM, La Greca RD, Zanaro NL, Palmer L, Sassetti B. Endothelial dysfunction, nitric oxide and platelet activation in hypertensive and diabetic type II patients. Thromb Res. 2001; 102(2):107-14.
63. Ojewole JA, Adewole SO, Olayiwola G. Hypoglycaemic and hypotensive effects of Momordica charantia Linn (Cucurbitaceae) whole-plant aqueous extract in rats. Cardiovasc J S Afr. 2006; 17(5):227-32.
64. Al-Salman J, Arjomand H, Kemp D G and Mittal M. Hepatocellular injury in a patient receiving rosiglitazone. Ann Intern Med. 2000; 132: 121-4.
65. Leibowitz G, Cerasi E. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? Diabetologia. 2001; 39:503-514.
66. Finegood DT, Mc-Arthur MD, Dunichand-Hoedl A, Thomas M J, Leonaed TB and Buckingham RE. The PPAR-γ agonist, rosiglitazone, reverses hyperinsulinemia and promotes growth of islet β-cell mass. Diabetes. 1998; 47(1): A47.
67. Smith S, Boam D, Bretherton-Watt D, Cawthorne MA, Moore G Loughborough S, Warrack J, Wilkinson M and Lis C. Rosiglitazone increases pancreatic islet area, density and insulin content, but not insulin gene expression. Diabetes1998; 47(1): A18.